AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02431572` - A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy	N/A

NCT number	NCT05679089
Study type	Observational
Source	Zhujiang Hospital
Contact	Hongbo Guo, MD, Ph.D
Phone	020-61643002
Email	guohongbo911@126.com
Status	Recruiting
Phase
Start date	November 1, 2022
Completion date	June 30, 2024

AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors — ASCEND-BRAIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms